Magselectofection: An integrated method of nanomagnetic separation and genetic modification of target cells

Blood

Volumn 117, Issue 16, 2011, Pages

  Sanchez Antequera, Yolanda ^a,f   Mykhaylyk, Olga ^a   Van Til, Niek P ^b   Cengizeroglu, Arzu ^c   De Jong, J Henk ^b   Huston, Marshall W ^b   Anton, Martina ^a   Johnston, Ian C D ^d   Pojda, Zygmunt ^e   Wagemaker, Gerard ^b   Plank, Christian ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF MUNICH   (Germany)

^d MILTENYI BIOTEC GMBH   (Germany)

^e INSTITUTE OF ONCOLOGY   (Poland)

^f INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; MAGNETIC NANOPARTICLE;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CELL COUNT; CELL CULTURE; CELL DIFFERENTIATION; CELL LINEAGE; CELL POPULATION; CELL SEPARATION; CONTROLLED STUDY; DNA MODIFICATION; ERYTHROID CELL; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE VECTOR; GENETIC ENGINEERING; GENETIC TRANSFECTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LENTIVIRINAE; LEUKEMIA CELL LINE; MAGNETIC FIELD; MAGSELECTOFECTION; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PURIFICATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TARGET CELL; UMBILICAL CORD; VIRAL GENE DELIVERY SYSTEM; WILD TYPE;

EID: 79956011574     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-302646     Document Type: Article

References (54)

1. Brill TH, Kubler HR, Pohla H, et al. Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial. Hum Gene Ther. 2009;20(12):1641-1651.
2. Collins SA, Guinn BA, Harrison PT, Scallan MF, O'Sullivan GC, Tangney M. Viral vectors in cancer immunotherapy: which vector for which strategy? Curr Gene Ther. 2008;8(2):66-78.
3. Goldman B, DeFrancesco L. The cancer vaccine roller coaster. Nat Biotechnol. 2009;27(2):129-139.
4. Bollard CM, Straathof KC, Huls MH, et al. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004;27(4):317-327. (Pubitemid 38833328)
5. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev. 2004;199(1):251-263. (Pubitemid 38744521)
6. Evans CH, Ghivizzani SC, Herndon JH, et al. Clinical trials in the gene therapy of arthritis. Clin Orthop. 2000;379(suppl):S300-S307.
7. Wehling P, Reinecke J, Baltzer AW, et al. Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis. Hum Gene Ther. 2009;20(2):97-101.
8. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360(5):447-458.
9. Cavazzana-Calvo M, Fischer A. Gene therapy for severe combined immunodeficiency: are we there yet? J Clin Invest. 2007;117(6):1456-1465. (Pubitemid 46871328)
10. Kumar S, Chanda D, Ponnazhagan S. Therapeutic potential of genetically modified mesenchymal stem cells. Gene Ther. 2008;15(10):711-715. (Pubitemid 351627354)
11. Wagner J, Kean T, Young R, Dennis JE, Caplan AI. Optimizing mesenchymal stem cell-based therapeutics. Curr Opin Biotechnol. 2009;20(5):531-536.
12. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3):533-546.
13. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126-129. (Pubitemid 44547756)
14. Biffi A, Capotondo A, Fasano S, et al. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J Clin Invest. 2006;116(11):3070-3082. (Pubitemid 44684492)
15. Cartier N, Aubourg P. Hematopoietic stem cell gene therapy in Hurler syndrome, globoid cell leukodystrophy, metachromatic leukodystrophy and X-adrenoleukodystrophy. Curr Opin Mol Ther. 2008;10(5):471-478.
16. van Til NP, Stok M, Aerts Kaya FS, et al. Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype. Blood. 2010;115(26):5329-5337.
17. Goessler UR, Riedel K, Hormann K, Riedel F. Perspectives of gene therapy in stem cell tissue engineering. Cells Tissues Organs. 2006;183(4):169-179. (Pubitemid 44924465)
18. Miltenyi S, Muller W, Weichel W, Radbruch A. High gradient magnetic cell separation with MACS. Cytometry. 1990;11(2):231-238. (Pubitemid 20097230)
19. Prince HM, Wall D, Rischin D, et al. CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy. Cytotherapy. 2002;4(2):147-155. (Pubitemid 34537334)
20. Mykhaylyk O, Antequera YS, Vlaskou D, Plank C. Generation of magnetic nonviral gene transfer agents and magnetofection in vitro. Nat Protoc. 2007;2(10):2391-2411.
21. Plank C, Anton M, Rudolph C, Rosenecker J, Krotz F. Enhancing and targeting nucleic acid delivery by magnetic force. Expert Opin Biol Ther. 2003;3(5):745-758. (Pubitemid 36934974)
22. Scherer F, Anton M, Schillinger U, et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther. 2002;9(2):102-109. (Pubitemid 34189525)
23. Furlani EP, Ng KC. Nanoscale magnetic biotransport with application to magnetofection. Phys Rev E Stat Nonlin Soft Matter Phys. 2008;77(6):061914.
24. Sauer AM, de Bruin KG, Ruthardt N, Mykhaylyk O, Plank C, Brauchle C. Dynamics of magnetic lipoplexes studied by single particle tracking in living cells. J Control Release. 2009;137(2):136-145.
25. Jeffery ND, McBain SC, Dobson J, Chari DM. Uptake of systemically administered magnetic nanoparticles (MNPs) in areas of experimental spinal cord injury (SCI). J Tissue Eng Regen Med. 2009;3(2):153-157.
26. Krotz F, de Wit C, Sohn HY, et al. Magnetofection: a highly efficient tool for antisense oligonucleotide delivery in vitro and in vivo. Mol Ther. 2003;7(5):700-710. (Pubitemid 36626250)
27. Namiki Y, Namiki T, Yoshida H, et al. A novel magnetic crystal-lipid nanostructure for magnetically guided in vivo gene delivery. Nat Nanotechnol. 2009;4(9):598-606.
28. Pickard M, Chari D. Enhancement of magnetic nanoparticle-mediated gene transfer to astrocytes by 'magnetofection': effects of static and oscillating fields. Nanomedicine (Lond). 2010;5(2):217-232.
29. Mykhaylyk O, Sanchez-Antequera Y, Vlaskou D, et al. Liposomal magnetofection. Methods Mol Biol. 2010;605:487-525.
30. Mykhaylyk O, Vlaskou D, Tresilwised N, Pithayanukul P, Moller W, Plank C. Magnetic nanoparticle formulations for DNA and siRNA delivery. J Magn Magn Mater. 2007;311(1):275-281. (Pubitemid 46401036)
31. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med. 1990;172(4):1217-1224. (Pubitemid 20343223)
32. Barry SC, Harder B, Brzezinski M, Flint LY, Seppen J, Osborne WR. Lentivirus vectors encoding both central polypurine tract and posttranscriptional regulatory element provide enhanced transduction and transgene expression. Hum Gene Ther. 2001;12(9):1103-1108. (Pubitemid 32692425)
33. Gimeno R, Weijer K, Voordouw A, et al. Monitoring the effect of gene silencing by RNA interference in human CD34+ cells injected into newborn RAG2-/- gammac-/- mice: functional inactivation of p53 in developing T cells. Blood. 2004;104(13):3886-3893. (Pubitemid 39620134)
34. Guilbert LJ, Iscove NN. Partial replacement of serum by selenite, transferrin, albumin and lecithin in haemopoietic cell cultures. Nature. 1976;263(5578):594-595.
35. Merchav S, Wagemaker G. Detection of murine bone marrow granulocyte/macrophage progenitor cells (GM-CFU) in serum-free cultures stimulated with purified M-CSF or GM-CSF. Int J Cell Cloning. 1984;2(6):356-367. (Pubitemid 15217389)
36. Wagemaker G, Visser TP. Erythropoietin-independent regeneration of erythroid progenitor cells following multiple injections of hydroxyurea. Cell Tissue Kinet. 1980;13(5):505-517. (Pubitemid 10039537)
37. Wognum AW, Visser TP, Peters K, Bierhuizen MF, Wagemaker G. Stimulation of mouse bone marrow cells with kit ligand, FLT3 ligand, and thrombopoietin leads to efficient retrovirus-mediated gene transfer to stem cells, whereas interleukin 3 and interleukin 11 reduce transduction of short- and long-term repopulating cells. Hum Gene Ther. 2000;11(15):2129-2141.
38. Sanchez-Antequera Y, Mykhaylyk O, Thalhammer S, Plank C. Gene delivery to Jurkat T cells using nonviral vectors associated with magnetic nanoparticles. Int J Biomed Nanosc Nanotechnol. 2010;1(2/3/4):202-229.
39. Plank C, Mykhaylyk O, Perea H, Aigner J, Steingoetter A, Botnar R. Nucleic acid delivery to magnetically labeled cells and its potential to modify cell engraftments. Hum Gene Ther. 2007;18(10):1059.
40. Kadota S, Kanayama T, Miyajima N, Takeuchi K, Nagata K. Enhancing of measles virus infection by magnetofection. J Virol Methods. 2005;128(1):61-66. (Pubitemid 40980210)
41. Hofmann A, Wenzel D, Becher UM, et al. Combined targeting of lentiviral vectors and positioning of transduced cells by magnetic nanoparticles. Proc Natl Acad Sci U S A. 2009;106(1):44-49.
42. Mykhaylyk O, Steingötter A, Perea H, Aigner J, Botnar R, Plank C. Nucleic acid delivery to magnetically labeled cells in a 2D array and at the luminal surface of cell culture tube and their detection by MRI. J Biomed Nanotechnol. 2009;5(6):692-706.
43. Wilhelm C, Gazeau F. Universal cell labelling with anionic magnetic nanoparticles. Biomaterials. 2008;29(22):3161-3174.
44. Ito CY, Li CY, Bernstein A, Dick JE, Stanford WL. Hematopoietic stem cell and progenitor defects in Sca-1/Ly-6A-null mice. Blood. 2003;101(2):517-523. (Pubitemid 36077572)
45. Cai S, Ernstberger A, Wang H, et al. In vivo selection of hematopoietic stem cells transduced at a low multiplicity-of-infection with a foamy viral MGMT(P140K) vector. Exp Hematol. 2008;36(3):283-292.
46. Song H, Song BW, Cha MJ, Choi IG, Hwang KC. Modification of mesenchymal stem cells for cardiac regeneration. Expert Opin Biol Ther. 2010;10(3):309-319.
47. Yang F, Green JJ, Dinio T, et al. Gene delivery to human adult and embryonic cell-derived stem cells using biodegradable nanoparticulate polymeric vectors. Gene Ther. 2009;16(4):533-546.
48. Aslan H, Zilberman Y, Arbeli V, et al. Nucleofection-based ex vivo nonviral gene delivery to human stem cells as a platform for tissue regeneration. Tissue Eng. 2006;12(4):877-889. (Pubitemid 43726529)
49. Kyriakou CA, Yong KL, Benjamin R, et al. Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFlk-1) following lentiviral-mediated gene transfer inhibit growth of Burkitt's lymphoma in a murine model. J Gene Med. 2006;8(3):253-264.
50. Pannell D, Osborne CS, Yao S, et al. Retrovirus vector silencing is de novo methylase independent and marked by a repressive histone code. EMBO J. 2000;19(21):5884-5894.
51. Koponen JK, Kekarainen T, Heinonen SE, et al. Umbilical cord blood-derived progenitor cells enhance muscle regeneration in mouse hindlimb ischemia model. Mol Ther. 2007;15(12):2172-2177. (Pubitemid 350148934)
52. Luo D, Saltzman WM. Enhancement of transfection by physical concentration of DNA at the cell surface. Nat Biotechnol. 2000;18(8):893-895. (Pubitemid 30640918)
53. Bulte JW. In vivo MRI cell tracking: clinical studies. AJR Am J Roentgenol. 2009;193(2):314-325.
54. Kraitchman DL, Bulte JW. In vivo imaging of stem cells and Beta cells using direct cell labeling and reporter gene methods. Arterioscler Thromb Vasc Biol. 2009;29(7):1025-1030.